What is it about?
Dear all, the article "Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy" concerns a very interesting and daily topic. Either you have not clear ideas of pro and cons of double lipid lowering agents therapy, or you need confirmation about how to manage this daily medical issue, this REVIEW and METANALYSIS is what you were waiting for.
Featured Image
Why is it important?
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy is: - very USEFUL and easily understandble - very COMPLETE review and metanalysis - UPDATED to the last researches and trials -rich of new and fresh unpublished explicative FIGURES - addresssed not only to CARDIOLOGISTS or specialists in INTERNAL MEDICINE, but also physician specialized in INFECTIOUS DISEASE, ENDOCRINOLOGY and PEDIATRICS (appropriate sections are present in) - addressed for GENERAL physician too - MEDICAL STUDENTS can find it very HELPFUL for their exams or thesis
Perspectives
The coauthors and me put all our passion and interest, and spent lot of time in searching, summarizing and enriching with tabs and figures the essential articles and trials about the pros and cons of the double lipid-lowering agents therapy. This was fresh food for our medical culture, and all we want is to share our knowledge and know readers point of views. Read it. It's made in Italy
Dr Nicola Tarantino
Universita degli Studi di Foggia
Read the Original
This page is a summary of: Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy, Vascular Health and Risk Management, February 2017, Dove Medical Press,
DOI: 10.2147/vhrm.s95044.
You can read the full text:
Contributors
The following have contributed to this page
